Tulane Patent for Therapeutic Compound Conjugates US12599674B2
Summary
The USPTO granted Patent US12599674B2 to The Administrators of the Tulane Educational Fund covering inventive therapeutic compound conjugates, pharmaceutical compositions, and related methods of treatment and manufacture. The patent, filed June 24, 2025, under application 19247100, contains 23 claims classified under A61K and A61P (oncology).
What changed
USPTO issued Patent US12599674B2 to The Administrators of the Tulane Educational Fund, granting exclusive rights to therapeutic compound conjugates (Formula (I)), pharmaceutical compositions containing those compounds, methods of treating diseases using the compounds, and methods for manufacturing the compounds. The patent contains 23 claims classified under A61K 47/643, A61K 9/19, and A61P 35/00 (oncology).
Competitors developing therapeutic conjugates in the oncology space should review this patent for potential infringement risks and consider design-around strategies or licensing options. Entities seeking to commercialize similar compound conjugates will need to evaluate freedom-to-operate and may benefit from reviewing the full patent claims to understand the scope of protection granted.
What to do next
- Monitor patent portfolio for freedom-to-operate implications
- Assess licensing opportunities for therapeutic compound conjugates
Archived snapshot
Apr 16, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Conjugates, their compositions, and their related methods
Grant US12599674B2 Kind: B2 Apr 14, 2026
Assignee
The Administrators of the Tulane Educational Fund
Inventors
Joseph A. Fuselier, David H. Coy
Abstract
Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I)). Other embodiments include compositions (e.g. pharmaceutical compositions) comprising the inventive compound. Still other embodiments of the invention include compositions for treating, for example, certain diseases using the inventive compounds. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating. Further embodiments include methods for making the inventive compound. Additional embodiments of the invention are also discussed herein.
CPC Classifications
A61K 47/643 A61K 9/19 A61P 35/00
Filing Date
2025-06-24
Application No.
19247100
Claims
23
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.